

## Curriculum Vitae

Name:	Andreas Michael Engert
Academic Title:	University Professor Dr. med.
Date of Birth:	April 29, 1959
Place of Birth:	Braunschweig, Germany
Nationality:	German
Family Status:	Married, four children
Professional Position:	<p>Full Professor at the Faculty of Medicine of the University of Cologne and Vice-Director, Department of Medicine I (Oncology, Hematology, Clinical Infectiology, Clinical Immunology, Hemostaseology; Internal intensive care)</p> <p>Chairman, German Hodgkin Study Group (GHSg)</p> <p>Coordinating Editor and Head, Cochrane Hematological Malignancies Group (CHMG)</p>
Current professional Core Areas:	<p>Hodgkin lymphoma and other malignancies</p> <p>Multicenter trials in malignant lymphoma</p> <p>Development of new immunotherapeutic approaches</p> <p>Evidence-based medicine</p>

Education:

1966-69 Primary school  
1969-78 Otto-Hahn-Gymnasium, Springe  
1978-86 Hannover Medical School; M.D.

Professional Career:

1986-88 University Hospital of Cologne, Prof. Dr. Volker Diehl: Internal medicine, hematology and oncology  
1988-90 Imperial Cancer Research Fund (London); Prof. Dr. Philip Thorpe: Antibody-based immunotherapy  
1990 Royal Free Hospital (London); Prof. Peter Amlot: Clinical immunology and tumor immunology  
1991-10 University Hospital of Cologne  
1991 Head, Laboratory for Immunotherapy  
1994 Board certificate Internal Medicine  
1995 Habilitation and postdoctoral thesis  
1995 Senior Physician and Assistant Medical Director  
1996-01 Medical Personnel Director  
1997 Board certificate Hematology/ Oncology  
1998 Secretary, Competence Network Mal. Lymphoma  
1999 Appointment as Deputy Medical Director  
1999 Secretary German Hodgkin Study Group  
2000 Coordinating Editor, Cochrane Hematological Malignancies Group  
2000 Appointment as full University Professor  
2007 Chairman, German Hodgkin Study Group (GHSG)

International:

1988-90 ICRF and Royal Free Hospital, London  
2004 European Healthcare Leadership Program, Paris  
2004 City of Hope Cancer Center, Los Angeles  
2005 MD Anderson Cancer Center  
2007 National Hematology Center, Belgrade  
2009 Peking and Guangzhou

Publications:

232 original papers

174 review articles

62 book articles

6 book editions

Köln, February 3, 2011

Prof. Dr. Andreas Engert

1. Borchmann P, Herbrecht R, Wilhelm M, Morschhauser F, Heß G, Cernohous P, Veals SA, Singer JW, Engert A. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. 2011 Apr;52(4):620-628.
2. Eichenauer DA, Engert A. One size for all in Hodgkin lymphoma? *Blood*. 2011 Mar 3;117(9):2557-8
3. Herbst C, Rehan FA, Skoetz N, Bohlius J, Brillant C, Schulz H, Monsef I, Specht L, Engert A. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. *Cochrane Database Syst Rev*. 2011 Feb 16;2:CD007110. Review
4. Hübel K, Weingart O, Naumann F, Bohlius J, Fresen MM, Engert A, Wheatley K. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. *Leuk Lymphoma*. 2011 Mar;52(3):444-57.
5. Skoetz N, Kluge S, Monsef I, Bauer K, Siebert H, Kreuzer KA, Engert A. Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors *J Natl Cancer Inst*. 2011 Feb 16;103(4):E1. Epub 2011 Jan 20.
6. Borchmann P, Engert A. The past: what we have learned in the last decade. *Hematology Am Soc Hematol Educ Program*. 2010;2010:101-7.
7. Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. *Blood*. 2011 Feb 17;117(7):2121-8. Epub 2010 Dec 16.
8. Herbst C, Engert A. Meta-analyses of early-stage hodgkin lymphoma. *Acta Haematol*. 2011;125(1-2):32-8. Epub 2010 Dec 8. Review.
9. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). *Nat Genet*. 2010 Dec;42(12):1126-30. Epub 2010 Oct 31.
10. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. *J Clin Oncol*. 2010 Dec 1;28(34):5074-80. Epub 2010 Oct 25.
11. Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, Engert A, Eich HT. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. *Expert Rev Anticancer Ther*. 2010 Sep;10(9):1419-28. Review.



12. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med*. 2010 Aug 12;363(7):640-52.
13. Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M; German Hodgkin's Lymphoma Study Group. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. *Ann Oncol*. 2011 Mar;22(3):681-8. Epub 2010 Aug 18.
14. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol*. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16.
15. Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v168-71.
16. Bauer K, Herbst C, Brillant C, Monsef I, Kluge S, Skoetz N, Engert A. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. *J Natl Cancer Inst*. 2010 Jun 16;102(12):E1.
17. Halbsguth TV, Nogová L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSg). *Blood*. 2010 Sep 23;116(12):2026-32. Epub 2010 Jun 15.
18. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSg HD15EPO trial. *J Clin Oncol*. 2010 May 1;28(13):2239-45. Epub 2010 Apr 5.
19. Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Plütschow A, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. *Ann Oncol*. 2010 Oct;21(10):2052-60. Epub 2010 Mar 19.
20. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. *Ann Neurol*. 2010 Feb;67(2):182-9.
21. Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U. Early complete response during



- chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. *Neuro Oncol.* 2010 Feb 16. [Epub ahead of print]
22. Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Engert A, Staak O, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies. *Nuklearmedizin.* 2010;49(3):97-105. Epub 2010 Feb 2.
  23. Böll B, Eichenauer DA, Von Tresckow B, Peine D, Hallek M, Engert A, Hübel K. Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. *Leuk Lymphoma.* 2010 Mar;51(3):562-4.
  24. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. *Haematologica.* 2010 Mar;95(3):494-500. Epub 2009 Nov 30. Review.
  25. Eichenauer DA, Bredenfeld H, Haverkamp H, Müller H, Franklin J, Fuchs M, Borchmann P, Müller-Hermelink HK, Eich HT, Müller RP, Diehl V, Engert A. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. *J Clin Oncol.* 2009 Dec 20;27(36):6079-85. Epub 2009 Nov 9.
  26. Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Böll B, Chalaris A, Simhadri VR, Wiegmann K, Krell HW, Rose-John S, Engert A, von Strandmann EP, Hansen HP. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. *Leukemia.* 2010 Jan;24(1):51-7. Epub 2009 Nov 5.
  27. Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? *Leuk Lymphoma.* 2009 Nov;50(11):1733-4.
  28. Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. *Br J Haematol.* 2010 Feb;148(3):480-2. Epub 2009 Oct 15.
  29. Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. *Onkologie.* 2009 Oct;32(10):599-604. Epub 2009 Sep 14.
  30. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol.* 2009 Sep 20;27(27):4548-54. Epub 2009 Aug 24.
  31. Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity *Clin Cancer Res.* 2009 Aug 15;15(16):5108-16. Epub 2009 Aug 11.
  32. Reiners KS, Gossmann A, von Strandmann EP, Böll B, Engert A, Borchmann P. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in

- patients with refractory and multiple relapsed Hodgkin lymphoma. *J Immunother.* 2009 Jun;32(5):508-12.
33. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD007303. Review.
  34. Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol.* 2009 May;20 Suppl 4:108-9. Review.
  35. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. *Lancet.* 2009 May 2;373(9674):1532-42. Erratum in: *Lancet.* 2009 Jul 4-2009 Jul 10;374(9683):28.
  36. Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and prognosis in malignant lymphomas. *Clin Lymphoma Myeloma.* 2009 Apr;9(2):160-6.
  37. Skoetz N, Weingart O, Monsef I, Bauer K, Brillant C, Herbst C, Kluge S, Engert A; Cochrane Haematological Malignancies Group. Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors. *J Natl Cancer Inst.* 2009 May 6;101(9):E1. Epub 2009 Apr 28. Review.
  38. Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma. *Cancer J.* 2009 Mar-Apr;15(2):143-9. Review.
  39. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. *Leuk Lymphoma.* 2009 Mar;50(3):374-9.
  40. Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT, Dietlein M, Engert A, Kozak T. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. *Ann Oncol.* 2009 Jul;20(7):1270-4. Epub 2009 Feb 19.
  41. Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, Engert A. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD007107. Review.
  42. Eichenauer DA, Engert A, Schulz H. Expanded use of rituximab in the management of non-Hodgkin lymphoma. *Onco Targets Ther.* 2009 Feb 18;2:189-97.
  43. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. *J Clin Oncol.* 2009 Jan 1;27(1):106-13. Epub 2008 Nov 24.
  44. Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D. Elevated pretreatment interleukin-10 serum level is an



- International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. *Leuk Lymphoma*. 2008 Nov;49(11):2091-8.
45. Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. *Haematologica*. 2009 Jan;94(1):150-2. Epub 2008 Nov 10.
  46. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IG, Schlegel U. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol*. 2009 Feb;91(3):299-305. Epub 2008 Oct 18.
  47. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. *PLoS One*. 2008;3(10):e3377. Epub 2008 Oct 13.
  48. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. *Cochrane Database Syst Rev*. 2008 Oct 8;(4):CD003189. Review
  49. Eichenauer DA, Fuchs M, Borchmann P, Engert A; German Hodgkin Study Group. Hodgkin's lymphoma: current treatment strategies and novel approaches. *Expert Rev Hematol*. 2008 Oct;1(1):63-73.
  50. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. *Blood*. 2008 Nov 15;112(10):3989-94. Epub 2008 Aug 29.
  51. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. *Ann Hematol*. 2009 Feb;88(2):121-32. Epub 2008 Aug 6. Review.
  52. Herbst C, Monsef I, Skötz N, Engert A; Cochrane Haematological Malignancies Group. Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia. *J Natl Cancer Inst*. 2008 Aug 6;100(15):E1. Epub 2008 Jul 29. Review.
  53. Quellmann S, Schwarzer G, Hübel K, Greb A, Engert A, Bohlius J. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. *Cochrane Database Syst Rev*. 2008 Jul 16;(3):CD004885. Review.
  54. Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A; German Hodgkin Study Group. Nodular lymphocyte-predominant Hodgkin lymphoma. *Curr Hematol Malig Rep*. 2008 Jul;3(3):126-31.
  55. Engert A. Treatment of lymphocyte-predominant Hodgkin lymphoma. *Ann Oncol*. 2008 Jun;19 Suppl 4:iv45-6. Review.
  56. Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A. Assessment of male fertility in patients with Hodgkin's lymphoma



- treated in the German Hodgkin Study Group (GHSg) clinical trials. *Ann Oncol*. 2008 Oct;19(10):1795-801. Epub 2008 Jun 9.
57. Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii65-6.
  58. Klimm B, Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. *Nat Clin Pract Oncol*. 2008 Jun;5(6):316-23. Epub 2008 May 6. Review.
  59. Quellmann S, Schwarzer G, Hübel K, Engert A, Bohlius J. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. *Leukemia*. 2008 Sep;22(9):1801-3. Epub 2008 May 1.
  60. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. *Blood*. 2008 Jun 15;111(12):5486-95. Epub 2008 Apr 4.
  61. Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. *Onkologie*. 2008 Feb;31(1-2):49-51. Epub 2008 Jan 22.
  62. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD004024. Review.
  63. Rothe A, Nathanielsz A, Oberhäuser F, von Pogge SE, Engert A, Hudson PJ, Power BE. Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient. *Biol Chem*. 2008 Apr;389(4):433-9.
  64. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütz M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. *J Dtsch Dermatol Ges*. 2008 May;6(5):366-73. Epub 2008 Jan 14. English, German.
  65. Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, Osterborg A. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. *Invest New Drugs*. 2008 Apr;26(2):139-49. Epub 2007 Dec 20.
  66. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A; German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. *J Clin Oncol*. 2008 Jan 20;26(3):434-9. Epub 2007 Dec 17.
  67. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A.



Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. *Immunity*. 2007 Dec;27(6):965-74. Epub 2007 Dec 6.

68. Schnell R, Barth S, Diehl V, Engert A. Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment. *BioDrugs*. 1997 Sep;8(3):216-34.
69. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. *Cochrane Database Syst Rev*. 2007 Oct 17;(4):CD003805. Review.
70. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). *Blood*. 2008 Jan 1;111(1):109-11. Epub 2007 Oct 15.
71. Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. *Hematol Oncol Clin North Am*. 2007 Oct;21(5):897-914. Review.
72. Diehl V, Engert A, Re D. Hodgkin's lymphoma: new insights in an old disease. Preface. *Hematol Oncol Clin North Am*. 2007 Oct;21(5):xiii-xiv.
73. Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, Engert A. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). *Blood*. 2008 Jan 1;111(1):71-6. Epub 2007 Sep 21.
74. Macann A, Bredenfeld H, Müller RP, Diehl V, Engert A, Eich HT. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. *Int J Radiat Oncol Biol Phys*. 2008 Jan 1;70(1):161-5. Epub 2007 Sep 12.
75. Weingart O, Rehan FA, Schulz H, Naumann F, Knaul I, Bohlius CB, Engert A. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma. *J Natl Cancer Inst*. 2007 Sep 5;99(17):E1. Epub 2007 Aug 28.
76. Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: a different disease in patients over 60. *Oncology (Williston Park)*. 2007 Jul;21(8):982-90; discussion 990, 996, 998 passim. Review.
77. Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hanseemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Müller RP; German Hodgkin Study Group. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). *Int J Radiat Oncol Biol Phys*. 2007 Nov 15;69(4):1187-92. Epub 2007 Aug 20.
78. Re D, Fuchs M, Schober T, Engert A, Diehl V. CNS involvement in Hodgkin's lymphoma. *J Clin Oncol*. 2007 Jul 20;25(21):3182.
79. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:



- final results of the GHSG HD7 trial. *J Clin Oncol*. 2007 Aug 10;25(23):3495-502. Epub 2007 Jul 2.
80. Rothe A, Nathanielsz A, Hosse RJ, Oberhäuser F, Strandmann EP, Engert A, Hudson PJ, Power BE. Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. *J Biotechnol*. 2007 Jul 15;130(4):448-54. Epub 2007 May 24.
  81. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *J Clin Oncol*. 2007 Jul 1;25(19):2764-9. Epub 2007 May 21.
  82. von Tresckow B, von Strandmann EP, Sasse S, Tawadros S, Engert A, Hansen HP. Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. *Haematologica*. 2007 May;92(5):682-5.
  83. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). *Haematologica*. 2007 Apr;92(4):568-9.
  84. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2007 May 2;99(9):706-14.
  85. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. *Cancer Treat Rev*. 2007 Jun;33(4):338-46. Epub 2007 Apr 2.
  86. Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. *Clin Pharmacokinet*. 2007;46(4):319-33.
  87. Renné C, Hinsch N, Willenbrock K, Fuchs M, Klapper W, Engert A, Küppers R, Hansmann ML, Bräuninger A. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. *Int J Cancer*. 2007 Jun 1;120(11):2504-9.
  88. Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. *Cancer Res*. 2007 Jan 1;67(1):332-8.
  89. Nogová L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. *Hematology Am Soc Hematol Educ Program*. 2006:266-72. Review.
  90. Sieniawski M, Staak O, Glossmann JP, Reineke T, Scheuss H, Diehl V, Engert A, Josting A. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. *Ann Hematol*. 2007 Feb;86(2):107-15. Epub 2006 Nov 14.

91. Klimm B, Eich HT, Haverkamp H, Lohri A, Koch P, Boissevain F, Trenn G, Worst P, Dühmke E, Müller RP, Müller-Hermelink K, Pfistner B, Diehl V, Engert A; German Hodgkin Study Group. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. *Ann Oncol*. 2007 Feb;18(2):357-63. Epub 2006 Oct 27.
92. Engert A, Herbrecht R, Santoro A, Zinzani PL, Gorbachevsky I. EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. *Clin Lymphoma Myeloma*. 2006 Sep;7(2):152-4.
93. Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hülsewede H, Engert A; Cochrane Haematological Malignancies Group. Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma. *J Natl Cancer Inst*. 2006 Aug 16;98(16):E2.
94. Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. *Expert Opin Pharmacother*. 2006 Aug;7(12):1641-51. Review.
95. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. *J Clin Oncol*. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24.
96. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. *J Natl Cancer Inst*. 2006 May 17;98(10):708-14. Review.
97. Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. *J Natl Cancer Inst*. 2006 May 3;98(9):620-5.
98. Kober T, Hülsewede H, Bohlius J, Engert A. Fourth biannual report of the Cochrane Haematological Malignancies Group. *J Natl Cancer Inst*. 2006 Apr 19;98(8):E1. Review.
99. Bohlius J, Engert A. Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. *Cancer Treat Rev*. 2006 May;32(3):234-8. Epub 2006 Apr 5.
100. Engert A, Bredenfeld H, Döhner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. *Haematologica*. 2006 Apr;91(4):546-9.
101. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin--an updated overview. *Nat Clin Pract Oncol*. 2006 Mar;3(3):152-64. Review.
102. Jensen M, Elter T, Engert A, Reiser M. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab. *Onkologie*. 2006 Mar;29(3):90-2. Epub 2006 Mar 3.
103. Nogová L, Diehl V, Engert A; German Hodgkin Study Group. Nodular lymphocyte-predominant Hodgkin's lymphoma. *Curr Hematol Malig Rep*. 2006 Mar;1(1):60-5. Review.



104. Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin's lymphoma. *Curr Hematol Malig Rep*. 2006 Mar;1(1):51-9. Review.
105. Rödel S, Engert A, Diehl V, Reiser M. Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. *Leuk Lymphoma*. 2005 Dec;46(12):1729-34.
106. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. *Haematologica*. 2005 Dec;90(12):1680-92. Review.
107. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol*. 2005 Oct 20;23(30):7555-64.
108. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M, Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. *Blood*. 2006 Mar 1;107(5):1955-62. Epub 2005 Oct 6.
109. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A; German Hodgkin Study Group. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. *J Clin Oncol*. 2005 Nov 1;23(31):8003-11. Epub 2005 Oct 3.
110. Trelle S, Staak JO, Jensen M, Engert A, Reiser M. Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital. *Onkologie*. 2005 Aug;28(8-9):407-11. Epub 2005 Aug 29.
111. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. *J Clin Oncol*. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.
112. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. *Br J Dermatol*. 2005 Sep;153(3):620-5.
113. Kober T, Skoetz N, Trelle S, Bohlius J, Engert A; Cochrane Haematological Malignancies Group. Third biannual report of the Cochrane Haematological Malignancies Group. *J Natl Cancer Inst*. 2005 Aug 17;97(16):E2. Review.
114. Nogová L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller RP, Diehl V, Engert A. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSg). *Ann Oncol*. 2005 Oct;16(10):1683-7. Epub 2005 Aug 10.
115. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaeyer K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A.



- Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. *J Clin Oncol*. 2005 Jul 20;23(21):4669-78.
116. Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, Diehl V, Josting A. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatin) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. *Leuk Lymphoma*. 2005 Jul;46(7):1017-22.
  117. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. *J Clin Oncol*. 2005 Aug 20;23(24):5739-45. Epub 2005 Jul 11
  118. Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. *Eur J Haematol Suppl*. 2005 Jul;(66):159-65. Review.
  119. Klimm B, Diehl V, Pfistner B, Engert A. Current treatment strategies of the German Hodgkin Study Group (GHSg). *Eur J Haematol Suppl*. 2005 Jul;(66):125-34. Review.
  120. Nogová L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K, Müller RP, Diehl V, Engert A. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes. *Eur J Haematol Suppl*. 2005 Jul;(66):106-10.
  121. Gossman A, Eich HT, Engert A, Josting A, Müller RP, Diehl V, Lackner KJ. CT and MR imaging in Hodgkin's disease--present and future. *Eur J Haematol Suppl*. 2005 Jul;(66):83-9. Review
  122. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases. *Eur J Haematol Suppl*. 2005 Jul;(66):77-82. Review.
  123. Engert A. Recombinant human erythropoietin in oncology: current status and further developments. *Ann Oncol*. 2005 Oct;16(10):1584-95. Epub 2005 Jun 15. Review.
  124. Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V; German Hodgkin's Study Group. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. *J Clin Oncol*. 2005 Aug 1;23(22):5052-60. Epub 2005 Jun 13.
  125. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. *Ann Oncol*. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6.
  126. Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. *Int J Radiat Oncol Biol Phys*. 2005 Nov 1;63(3):860-5. Epub 2005 May 31.
  127. Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E. The fully human anti-CD30 antibody 5F11 activates NF- $\kappa$ B and sensitizes lymphoma cells to bortezomib-induced apoptosis. *Blood*. 2005 Sep 1;106(5):1839-42. Epub 2005 May 5.



128. Vaupel P, Dunst J, Engert A, Fandrey J, Feyer P, Freund M, Jelkmann W. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. *Onkologie*. 2005 Apr;28(4):216-21. Epub 2005 Mar 31
129. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. *J Natl Cancer Inst*. 2005 Apr 6;97(7):489-98. Review
130. Kober T, Bohlius J, Trelle S, Engert A. Second biannual report of the Cochrane Haematological Malignancies Group. *J Natl Cancer Inst*. 2005 Apr 6;97(7):E1. Review.
131. Bohlius JF, Langensiepen S, Engert A, Schwarzer G, Bennett CL. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. *Best Pract Res Clin Haematol*. 2005;18(3):449-54. Review.
132. Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner W, Pogge von Strandmann E, Schicha H, Engert A, Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. *Eur J Haematol*. 2005 Apr;74(4):348-52.
133. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. *Ann Hematol*. 2005 Aug;84(8):517-25. Epub 2005 Mar 10.
134. Hartmann P, Lammertink J, Mansmann G, Hübel K, Salzberger B, Stützer H, Engert A, Fätkenheuer G. A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. *Eur J Med Res*. 2005 Jan 28;10(1):29-35.
135. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. *J Clin Oncol*. 2005 Mar 1;23(7):1522-9. Epub 2005 Jan 4.
136. Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin's lymphoma. *Curr Hematol Rep*. 2005 Jan;4(1):15-22. Review.
137. Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol*. 2005 Jan;16(1):124-31.
138. Rothe A, Klimka A, Tur MK, Pfizner T, Huhn M, Sasse S, Mallmann P, Engert A, Barth S. Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. *Int J Mol Med*. 2004 Oct;14(4):729-35.
139. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, von Strandmann EP. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. *J Immunother*. 2004 Sep-Oct;27(5):347-53



140. Trelle S, Higgins G, Kober T, Engert A. Biannual report of the Cochrane Haematological Malignancies Group. *J Natl Cancer Inst*. 2004 Aug 4;96(15):E2.
141. Rothe A, Schulz H, Elter T, Engert A, Reiser M. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. *Haematologica*. 2004 Jul;89(7):875-6.
142. Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. *Int J Cancer*. 2004 Sep 10;111(4):568-74.
143. Schaefer H, Engert A, Grass G, Mansmann G, Wassmer G, Hubel K, Loehlein D, Ulrich BC, Lippert H, Knoefel WT, Hoelscher AH. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. *Ann Surg*. 2004 Jul;240(1):68-75.
144. Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, Engert A; German Hodgkin Lymphoma Study Group. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. *Ann Oncol*. 2004 Jul;15(7):1079-85.
145. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. *Haematologica*. 2004 Jun;89(6):753-4.
146. Eich HT, Staar S, Gossmann A, Engert A, Franklin J, Sieber M, Krug B, Diehl V, Lackner KJ, Müller RP; German Hodgkin Lymphoma Study Group. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging. *Am J Clin Oncol*. 2004 Jun;27(3):279-84.
147. Reiners KS, Hansen HP, Krüssmann A, Schön G, Csernok E, Gross WL, Engert A, Von Strandmann EP. Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen. *Immunology*. 2004 Jun;112(2):228-36.
148. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol*. 2004 Jun 15;22(12):2424-9. Epub 2004 May 10.
149. Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, Colombatti M. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. *Clin Exp Immunol*. 2004 May;136(2):365-72.
150. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). *Leukemia*. 2004 Jun;18(6):1093-101.



151. von Tresckow B, Kallen KJ, von Strandmann EP, Borchmann P, Lange H, Engert A, Hansen HP. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. *J Immunol*. 2004 Apr 1;172(7):4324-31.
152. Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP, Lange H, Lemke H, Engert A. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. *FASEB J*. 2004 May;18(7):893-5. Epub 2004 Mar 19.
153. Eich HT, Staar S, Gossmann A, Hansemann K, Skripnitchenko R, Kocher M, Semrau R, Engert A, Josting A, Franklin J, Krug B, Diehl V, Müller RP; German Hodgkin Study Group. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. *Int J Radiat Oncol Biol Phys*. 2004 Mar 15;58(4):1121-7.
154. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duhmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. *Ann Oncol*. 2004 Feb;15(2):276-82.
155. Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, Karthaus M, Fätkenheuer G, Bethe U, Tintelnot K, Cornely OA. Combination therapy of disseminated *Fusarium oxysporum* infection with terbinafine and amphotericin B. *Ann Hematol*. 2004 Jun;83(6):394-7. Epub 2003 Nov 27.
156. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. *J Clin Oncol*. 2003 Dec 15;21(24):4489-95. Epub 2003 Nov 3.
157. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. *Onkologie*. 2003 Aug;26(4):351-4. Review.
158. Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Günther H, Pfreundschuh DM, Camboni G, Engert A. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. *Haematologica*. 2003 Aug;88(8):888-94.
159. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loeffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol*. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11.



160. Glossmann JP, Engert A, Wassmer G, Flechtner H, Ko Y, Rudolph C, Metzner B, Dörken B, Wiedenmann S, Diehl V, Josting A. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial. *Ann Hematol.* 2003 Aug;82(8):469-75. Epub 2003 Jun 21.
161. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. *Blood.* 2003 Nov 15;102(10):3737-42. Epub 2003 Jul 24.
162. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. *Br J Haematol.* 2003 Aug;122(3):413-23. Review.
163. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol.* 2003 May 1;21(9):1734-9.
164. Hübel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. *Ann Hematol.* 2003 Apr;82(4):207-13. Epub 2003 Mar 6. Review.
165. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. *Ann Oncol.* 2003 May;14(5):729-36.
166. Stöcker M, Tur MK, Sasse S, Krüssmann A, Barth S, Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. *Protein Expr Purif.* 2003 Apr;28(2):211-9.
167. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol.* 2003 Sep 15;21(18):3440-6. Epub 2003 Mar 7.
168. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). *Br J Dermatol.* 2003 Mar;148(3):602-3.
169. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. *Ann Oncol.* 2003 Apr;14(4):520-35. Review. Erratum in: *Ann Oncol.* 2003 Jun;14(6):967.
170. Philipp J, Dienst A, Unruh M, Wagener A, Grunow A, Engert A, Fries JW, Gottstein C. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. *Arterioscler Thromb Vasc Biol.* 2003 May 1;23(5):905-10. Epub 2003 Mar 20.
171. Tur MK, Rothe A, Huhn M, Goerres U, Klimka A, Stöcker M, Engert A, Fischer R, Finner R, Barth S. A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. *Int J Mol Med.* 2003 Apr;11(4):523-7.



172. Hübel K, Engert A. Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy. *Onkologie*. 2003 Feb;26(1):73-9. Review.
173. Krause AS, Weihrauch MR, Bode U, Fleischhack G, Elter T, Heuer T, Engert A, Diehl V, Josting A. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. *Leuk Lymphoma*. 2002 Nov;43(11):2139-43.
174. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, Driessen C, Rudiger T, Muller-Hermelink K, Diehl V, Engert A; German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. *Blood*. 2003 Jan 15;101(2):420-4.
175. Adili F, Scholz T, Hille M, Heckenkamp J, Barth S, Engert A, Schmitz-Rixen T. Photodynamic therapy mediated induction of accelerated re-endothelialisation following injury to the arterial wall: implications for the prevention of postinterventional restenosis. *Eur J Vasc Endovasc Surg*. 2002 Aug;24(2):166-75.
176. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. *Blood*. 2002 Nov 1;100(9):3115-20.
177. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. *Blood*. 2002 Nov 1;100(9):3101-7.
178. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol*. 2002 Oct;13(10):1628-35.
179. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. *J Neurooncol*. 2002 Sep;59(3):213-6.
180. Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A; German Hodgkin's Lymphoma Study Group (GHSG). A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). *Ann Hematol*. 2002 Aug;81(8):424-9. Epub 2002 Aug 15.
181. Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, Engert A. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. *Leuk Lymphoma*. 2002 Apr;43(4):805-11.
182. Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. *Ann Oncol*. 2002;13 Suppl 1:57-66. Review.
183. Josting A, Raemakers JM, Diehl V, Engert A. New concepts for relapsed Hodgkin's disease. *Ann Oncol*. 2002;13 Suppl 1:117-21. Review.



184. Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. *Ann Oncol.* 2002;13 Suppl 1:112-6. Review.
185. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. *Clin Cancer Res.* 2002 Jun;8(6):1779-86.
186. Pfitzner T, Reiser M, Barth S, Borchmann P, Schulz H, Schinköthe T, Oberhäuser F, Wessels J, Tur M, Diehl V, Engert A. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. *Ann Hematol.* 2002 May;81(5):258-66. Epub 2002 Apr 9.
187. Pfister K, Wittig BM, Jüngling B, Ecker KW, Barth S, Huhn M, Sasse S, Engert A, Mueller-Molaian I, Diehl V, Zeitz M, Stallmach A. The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice. *Int J Colorectal Dis.* 2002 Mar;17(2):77-84.
188. Hansen HP, Matthey B, Barth S, Kisseleva T, Mokros T, Davies SJ, Beckett RP, Foelster-Holst R, Lange HH, Engert A, Lemke H. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. *Int J Cancer.* 2002 Mar 10;98(2):210-5.
189. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. *Ann Hematol.* 2002 Jan;81(1):26-32. Epub 2001 Dec 14.
190. Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. *J Clin Oncol.* 2002 Jan 15;20(2):476-84.
191. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. *J Clin Oncol.* 2002 Jan 1;20(1):221-30.
192. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. *Cancer Res.* 2001 Dec 15;61(24):8737-42.
193. Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. *Ann Oncol.* 2001 Sep;12(9):1307-11.
194. Tur MK, Sasse S, Stöcker M, Djabelkhir K, Huhn M, Matthey B, Gottstein C, Pfitzner T, Engert A, Barth S. An anti-GD2 single chain Fv selected by phage display and



- fused to *Pseudomonas* exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. *Int J Mol Med*. 2001 Nov;8(5):579-84.
195. Reiser M, Bredenfeld H, Engert A, Diehl V. The role of ifosfamide in the treatment of relapsed and refractory lymphoma. *Eur J Haematol Suppl*. 2001 Jul;64:37-40. Review.
  196. Reiser M, Josting A, Diehl V, Engert A. Primary lymphoma of the conjunctiva--a rare manifestation of indolent non-Hodgkin's lymphoma. *Ann Hematol*. 2001 May;80(5):311-3.
  197. Schulz H, Winkler U, Staak JO, Engert A. The Monoclonal Antibodies Campath-1H and Rituximab in the Therapy of Chronic Lymphocytic Leukemia. *Onkologie*. 2000 Dec;23(6):526-532.
  198. Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, Hübel K, Staib P, Schulz A, Diehl V, Engert A. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. *Ann Oncol*. 2001 May;12(5):661-7.
  199. Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochters A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. *J Clin Oncol*. 2001 Jun 1;19(11):2905-14.
  200. Rueffer U, Josting A, Franklin J, May M, Sieber M, Breuer K, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. *J Clin Oncol*. 2001 Apr 1;19(7):2026-32.
  201. Tur MK, Huhn M, Sasse S, Engert A, Barth S. Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. *Biotechniques*. 2001 Feb;30(2):404-8, 410, 412-3.
  202. Sundarapandian K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. *J Immunol Methods*. 2001 Feb 1;248(1-2):113-23.
  203. Hübel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. *J Infect Dis*. 2001 Jan 15;183(2):321-328. Epub 2000 Dec 8. Review.
  204. Hübel K, Mansmann G, Schäfer H, Oberhäuser F, Diehl V, Engert A. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. *Cytokine*. 2000 Dec;12(12):1797-800.
  205. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W. 230. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. *Ann Hematol*. 2000 Sep;79(9):493-500.
  206. Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review). *Int J Mol Med*. 2000 Nov;6(5):509-14. Review.



207. Scheid C, Reiser M, Draube A, Josting A, Fuchs M, Chemnitz J, Winter S, Schultz A, Engert A, Diehl V, Söhngen D. Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF. *J Hematother Stem Cell Res.* 2000 Aug;9(4):411-3
208. Barth S, Weidenmüller U, Tur MK, Schmidt MF, Engert A. Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage display. *J Mol Biol.* 2000 Aug 25;301(4):751-7.
209. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. *Blood.* 2000 Aug 15;96(4):1280-6.
210. Tesch H, Engert A, Manzke O, Diehl V, Bohlen H. Treatment of patients with malignant lymphomas with monoclonal antibodies. *Bone Marrow Transplant.* 2000 May;25 Suppl 2:S50-3. Review.
211. Klimka A, Matthey B, Roovers RC, Barth S, Arends JW, Engert A, Hoogenboom HR. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. *Br J Cancer.* 2000 Jul;83(2):252-60. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T, Diehl V, Engert A. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. *Blood.* 2000 Jun 15;95(12):3909-14.
212. Schäfer H, Hübel K, Bohlen H, Mansmann G, Hegener K, Richarz B, Oberhäuser F, Wassmer G, Hölscher AH, Pichlmaier H, Diehl V, Engert A. Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy. *Ann Hematol.* 2000 Mar;79(3):143-51
213. Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinköthe T, Lorenzen J, Diehl V, Engert A. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. *Int J Cancer.* 2000 Jun 1;86(5):718-24.
214. Pfitzner T, Engert A, Wittor H, Schinköthe T, Oberhäuser F, Schulz H, Diehl V, Barth S. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. *Leukemia.* 2000 Apr;14(4):754-66.
215. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. *Appl Environ Microbiol.* 2000 Apr;66(4):1572-9.
216. Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A. DEXA-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. *Leuk Lymphoma.* 2000 Mar;37(1-2):185-7
217. Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (DEXA-BEAM) followed by high-dose chemotherapy and stem cell rescue - a highly effective regimen for patients with refractory or relapsed indolent lymphoma. *Leuk Lymphoma.* 2000 Mar;37(1-2):115-23.



218. Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. *Ann Oncol.* 2000;11 Suppl 1:81-5. Review.
219. Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. *Leukemia.* 2000 Jan;14(1):129-35.
220. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? *J Clin Oncol.* 2000 Jan;18(2):332-9.
221. Rueffer U, Sieber M, Josting A, Breuer K, Grotenhermen FJ, Bredenfeld H, Tesch H, Nisters-Backes H, Engert A, Diehl V. Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG. *Ann Oncol.* 1999 Nov;10(11):1343-8.
222. Barth S, Matthey B, Huhn M, Diehl V, Engert A. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma. *Cytokines Cell Mol Ther.* 1999 Jun;5(2):69-78.
223. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). *Blood.* 1999 Oct 1;94(7):2217-24.
224. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches. *Semin Hematol.* 1999 Jul;36(3):282-9. Review.
225. Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. *Bone Marrow Transplant.* 1999 Jun;23(12):1223-8.
226. Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H, Arends JW, Diehl V, Hoogenboom HR, Engert A. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. *Br J Cancer.* 1999 Jun;80(8):1214-22.
227. Reiser M, Josting A, Dias Wickramanayake P, Draube A, Scheid C, Tesch H, Wolf J, Diehl V, Engert A. Dexamethasone-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. *Leuk Lymphoma.* 1999 Apr;33(3-4):305-12.
228. Matthey B, Engert A, Klimka A, Diehl V, Barth S. *Gene.* 1999 Mar 18;229(1-2):145-53. 258. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
229. Hübel K, Hegener K, Schnell R, Mansmann G, Oberhäuser F, Staib P, Diehl V, Engert A. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. *Ann Hematol.* 1999 Feb;78(2):73-7.
230. Borchmann P, Schnell R, Diehl V, Engert A. New drugs in the treatment of Hodgkin's disease. *Ann Oncol.* 1998;9 Suppl 5:S103-8. Review.



231. Wolf J, Tesch H, Parsa-Parsi R, Engert A, Diehl V. Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives. *Ann Oncol.* 1998;9 Suppl 5:S79-82. Review.
232. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. *Ann Oncol.* 1998;9 Suppl 5:S67-71. Review.
233. Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. *Leuk Lymphoma.* 1998 Oct;31(3-4):359-66.
234. Barth S, Huhn M, Wels W, Diehl V, Engert A. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. *Int J Mol Med.* 1998 Jan;1(1):249-56.
235. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol.* 1998 Dec;16(12):3810-21.
236. Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Brunsch U, Tirier C, Müller U, Loeffler M. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. *Blood.* 1998 Dec 15;92(12):4560-7.
237. Wolf J, Engert A, Diehl V. Issues in the treatment of Hodgkin's disease. *Curr Opin Oncol.* 1998 Sep;10(5):396-402. Review.
238. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. *J Clin Oncol.* 1998 Oct;16(10):3257-63.
239. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). *Ann Hematol.* 1998 Jul-Aug;77(1-2):89-91.
240. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20



- monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood*. 1998 Sep 15;92(6):1927-32.
241. Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. *Leuk Lymphoma*. 1998 Aug;30(5-6):525-37.
  242. Engert A, Sausville EA, Vitetta E. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. *Curr Top Microbiol Immunol*. 1998;234:13-33.
  243. Josting A, Kätay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). *Ann Oncol*. 1998 Mar;9(3):289-95.
  244. Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma. *Leukemia*. 1997 Dec;11 Suppl 5:S47-51.
  245. Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. *Cancer Res*. 1997 May 1;57(9):1704-9.
  246. Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. *Int J Clin Pharmacol Ther*. 1997 Feb;35(2):80-3. Review.
  247. Engert A, Schnell R, Küpper F, Reiser M, Engelhard M, Wilhelm M, Lathan B, Baltes-Engler S, Winterhalter B, Scheulen ME, Dederichs B, Tesch H, Wörmann B, Diehl V. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma. *Leuk Lymphoma*. 1997 Feb;24(5-6):513-22.
  248. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. *Blood*. 1997 Jan 15;89(2):403-10.
  249. Winkler U, Barth S, Schnell R, Diehl V, Engert A. The emerging role of immunotoxins in leukemia and lymphoma. *Ann Oncol*. 1997;8 Suppl 1:139-46. Review.
  250. Bohlen H, Thielemanns K, Tesch H, Engert A, Wolf HJ, van Camp B, Urbain J, Diehl V. Idiotypic vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. *Cytokines Mol Ther*. 1996 Dec;2(4):231-8.
  251. Klimka A, Barth S, Drillich S, Wels W, van Snick J, Renauld JC, Tesch H, Bohlen H, Diehl V, Engert A. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. *Cytokines Mol Ther*. 1996 Sep;2(3):139-46.
  252. Schnell R, Barth S, Diehl V, Engert A. Hodgkin's disease. Future treatment strategies: fact or fiction? *Baillieres Clin Haematol*. 1996 Sep;9(3):573-93. Review.



253. Schnell R, Katouzi AA, Linnartz C, Schoen G, Drillich S, Hansmann ML, Schiefer D, Barth S, Zangemeister-Wittke U, Stahel RA, Diehl V, Engert A. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. *Int J Cancer*. 1996 May 16;66(4):526-31.
254. Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trümper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser ED, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. *Leukemia*. 1996 May;10(5):836-43.
255. Westermann F, Kube D, Haier B, Bohlen H, Engert A, Zuehlsdorf M, Diehl V, Tesch H. Interleukin 10 inhibits cytokine production of human AML cells. *Ann Oncol*. 1996 Apr;7(4):397-404.
256. Barth S, Schnell R, Diehl V, Engert A. Development of immunotoxins for potential clinical use in Hodgkin's disease. *Ann Oncol*. 1996;7 Suppl 4:135-41. Review
257. Reuss K, Engert A, Tesch H, Diehl V. Current clinical trials in Hodgkin's disease. *Ann Oncol*. 1996;7 Suppl 4:109-13. Review
258. Ghetie V, Engert A, Schnell R, Vitetta ES. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. *Cancer Lett*. 1995 Nov 27;98(1):97-101.
259. Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. *Int J Cancer*. 1995 Oct 9;63(2):304-9.
260. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, Diehl V, Hoelzer D. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. *Leuk Lymphoma*. 1995 Aug;18(5-6):485-92.
261. Gottstein C, Schön G, Tawadros S, Kube D, Wargalla-Plate UC, Hansmann ML, Wacker HH, Berthold F, Diehl V, Engert A. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. *Cancer Res*. 1994 Dec 1;54(23):6186-93.
262. Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. *Leuk Lymphoma*. 1994 May;13(5-6):441-8. Review.
263. Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. *Blood*. 1994 Jan 15;83(2):466-75.
264. Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. Immunotoxins: is there a clinical value? *Ann Oncol*. 1994;5 Suppl 1:97-103. Review.
265. Engelhard M, Gerhartz H, Brittinger G, Engert A, Fuchs R, Geiseler B, Gerhartz D, Haunau AR, Hartlapp HJ, Huhn D, et al. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind



- placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. *Ann Oncol.* 1994;5 Suppl 2:123-5.
266. Kapp U, Dux A, Schell-Frederick E, Banik N, Hummel M, Mücke S, Fonatsch C, Bullerdiek J, Gottstein C, Engert A, et al. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice. *Ann Oncol.* 1994;5 Suppl 1:121-6.
  267. Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert J, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. *Semin Oncol.* 1993 Oct;20(5 Suppl 7):28-31.
  268. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. *Blood.* 1993 Sep 15;82(6):1803-12.
  269. von Kalle C, Wolf J, Becker A, Scaer A, Munck M, Engert A, Kapp U, Fonatsch C, Komitowski D, Feaux de Lacroix W, et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. *Int J Cancer.* 1992 Dec 2;52(6):887-91.
  270. Kapp U, Wolf J, von Kalle C, Tawadros S, Röttgen A, Engert A, Fonatsch C, Stein H, Diehl V. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. *Ann Oncol.* 1992 Sep;3 Suppl 4:21-3.
  271. Diehl V, Engert A. An overview of the Second International Symposium on Hodgkin's disease. *Ann Oncol.* 1992 Sep;3 Suppl 4:1-3.
  272. Engert A, Pohl C, Diehl V. Experimental therapy in Hodgkin's disease. *Ann Oncol.* 1992 Sep;3 Suppl 4:97-100.
  273. Engert A, Martin G, Amlot P, Wijdenes J, Diehl V, Thorpe P. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. *Int J Cancer.* 1991 Sep 30;49(3):450-6.
  274. Engert A, Brown A, Thorpe P. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. *Leuk Res.* 1991;15(11):1079-86.
  275. Engert A, Diehl V. Controversies in the management of non-Hodgkin lymphoma. *Eur J Cancer.* 1991;27(3):309-15. Review
  276. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. *Cancer Res.* 1990 Nov 1;50(21):6944-8.
  277. Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. *Cancer Res.* 1990 May 15;50(10):2929-35.
  278. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. *Cancer Res.* 1990 Jan 1;50(1):84-8.
  279. Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Phase I trial of recombinant interleukin-2 and

- cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. *J Biol Response Mod.* 1988 Oct;7(5):457-72
280. Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. *Invest New Drugs.* 1988 Sep;6(3):179-88.
281. Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, et al. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2. *J Biol Response Mod.* 1987 Aug;6(4):412-29.
282. Fonatsch C, Stollmann B, Holldack J, Engert A. Translocation (6;9)(p23;q34) in smoldering leukemia and acute nonlymphocytic leukemia. *Cancer Genet Cytogenet.* 1987 Jun;26(2):363-8.
283. Engert A, Kirchner HH, Schaadt M, Diehl V. Intracranial transplantation of human hematopoietic cell lines in nude mice: a preclinical screening model for cytostatic drugs. *Anticancer Res.* 1987 Jan-Feb;7(1):49-53.